SI3157531T1 - Metode in pripravki za stimulacijo črevesnega enteroendkrinega sistema za zdravljenje bolezni ali stanj, ki so povezani z le-tem - Google Patents
Metode in pripravki za stimulacijo črevesnega enteroendkrinega sistema za zdravljenje bolezni ali stanj, ki so povezani z le-temInfo
- Publication number
- SI3157531T1 SI3157531T1 SI201531637T SI201531637T SI3157531T1 SI 3157531 T1 SI3157531 T1 SI 3157531T1 SI 201531637 T SI201531637 T SI 201531637T SI 201531637 T SI201531637 T SI 201531637T SI 3157531 T1 SI3157531 T1 SI 3157531T1
- Authority
- SI
- Slovenia
- Prior art keywords
- stimulation
- compositions
- methods
- same
- treating diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015657P | 2014-06-23 | 2014-06-23 | |
| US14/329,627 US10040817B2 (en) | 2013-10-03 | 2014-07-11 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| EP15811714.3A EP3157531B1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| PCT/US2015/036935 WO2015200195A1 (en) | 2014-06-23 | 2015-06-22 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3157531T1 true SI3157531T1 (sl) | 2021-09-30 |
Family
ID=54869043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531637T SI3157531T1 (sl) | 2014-06-23 | 2015-06-22 | Metode in pripravki za stimulacijo črevesnega enteroendkrinega sistema za zdravljenje bolezni ali stanj, ki so povezani z le-tem |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US10040817B2 (enExample) |
| EP (1) | EP3157531B1 (enExample) |
| JP (2) | JP6692300B2 (enExample) |
| CN (2) | CN113559108A (enExample) |
| BR (1) | BR112016029917A2 (enExample) |
| CA (1) | CA2951720C (enExample) |
| CY (1) | CY1124554T1 (enExample) |
| DK (1) | DK3157531T3 (enExample) |
| ES (1) | ES2878077T3 (enExample) |
| HR (1) | HRP20211005T1 (enExample) |
| HU (1) | HUE054828T2 (enExample) |
| LT (1) | LT3157531T (enExample) |
| MX (2) | MX382442B (enExample) |
| PL (1) | PL3157531T3 (enExample) |
| PT (1) | PT3157531T (enExample) |
| RS (1) | RS62064B1 (enExample) |
| SI (1) | SI3157531T1 (enExample) |
| SM (1) | SMT202100373T1 (enExample) |
| WO (1) | WO2015200195A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| WO2018222665A1 (en) * | 2017-05-31 | 2018-12-06 | Enterin Laboratories, Inc. | Methods and compositions for preventing or treating inflammatory diseases |
| EP3678671A4 (en) * | 2017-09-08 | 2022-12-07 | Enterin, Inc. | METHODS OF TREATMENT OF SLEEPING DISEASES, SLEEP DISORDERS AND RELATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS |
| MA50536A (fr) * | 2017-10-30 | 2020-09-09 | Enterin Inc | Nouvelles formes solides de squalamine et procédés pour les produire |
| KR20200146038A (ko) * | 2018-03-27 | 2020-12-31 | 엔테린, 인코포레이티드 | 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물 |
| JP2021527090A (ja) * | 2018-06-13 | 2021-10-11 | エンターイン、 インコーポレイテッドＥｎｔｅｒｉｎ， Ｉｎｃ． | 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
| WO2020028791A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Low dosage intranasal aminosterol dosage forms and methods of using the same |
| US20210315907A1 (en) * | 2018-08-03 | 2021-10-14 | Enterin, Inc, | Compositions and methods for treating brain-gut disorders |
| US20230125585A1 (en) * | 2019-08-02 | 2023-04-27 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
| CN115551871A (zh) * | 2020-03-19 | 2022-12-30 | 因特尔公司 | 角鲨胺的晶型 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
| CA2157594A1 (en) | 1993-03-10 | 1994-09-15 | Leah L. Frye | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
| US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| AU3512595A (en) | 1994-09-13 | 1996-03-29 | Magainin Pharmaceuticals, Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| US5834453A (en) | 1995-05-30 | 1998-11-10 | Lehigh University | Methods for the manufacture and use of antimicrobial sterol conjugates |
| US5795885A (en) | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
| AU723663C (en) * | 1995-06-07 | 2001-11-01 | Magainin Pharmaceuticals, Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds |
| US5994336A (en) | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
| US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
| US5840936A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US5744453A (en) | 1996-01-05 | 1998-04-28 | Mintz; Clifford S. | Polyamine conjugates for treatment of infection |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| PT910382E (pt) | 1996-04-26 | 2003-10-31 | Genaera Corp | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| JP2002515035A (ja) | 1996-05-17 | 2002-05-21 | ジェネーラ・コーポレーション | アミノステロール化合物の治療学的使用 |
| WO1998019682A1 (en) | 1996-11-01 | 1998-05-14 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and uses therefor |
| CA2339174C (en) | 1998-08-12 | 2009-01-06 | Magainin Pharmaceuticals, Inc. | Aminosterol compounds and uses thereof |
| US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| AU2002230398A1 (en) | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| WO2002044324A2 (en) * | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| ES2716404T3 (es) * | 2002-01-28 | 2019-06-12 | Kyowa Hakko Kogyo Kk | Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US7981876B2 (en) | 2005-04-25 | 2011-07-19 | Ohr Pharmaceuticals, Inc. | Polymorphic and amorphous salt forms of squalamine dilactate |
| CA2985271A1 (en) | 2007-09-06 | 2009-03-12 | Ohr Pharmaceutical, Inc. | A method for treating diabetes |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| WO2011056650A2 (en) | 2009-10-27 | 2011-05-12 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| WO2011066260A2 (en) | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
| KR20150003798A (ko) | 2012-04-20 | 2015-01-09 | 오에이치알 파마서티컬, 인코포레이티드 | Ptp1b 연관 질병의 치료용 아미노스테로이드 |
| CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
| EP2934543B1 (en) | 2012-12-20 | 2018-10-31 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2014
- 2014-07-11 US US14/329,627 patent/US10040817B2/en active Active
-
2015
- 2015-06-22 EP EP15811714.3A patent/EP3157531B1/en active Active
- 2015-06-22 LT LTEP15811714.3T patent/LT3157531T/lt unknown
- 2015-06-22 BR BR112016029917A patent/BR112016029917A2/pt not_active Application Discontinuation
- 2015-06-22 HR HRP20211005TT patent/HRP20211005T1/hr unknown
- 2015-06-22 DK DK15811714.3T patent/DK3157531T3/da active
- 2015-06-22 CN CN202110489234.7A patent/CN113559108A/zh active Pending
- 2015-06-22 MX MX2016017368A patent/MX382442B/es unknown
- 2015-06-22 WO PCT/US2015/036935 patent/WO2015200195A1/en not_active Ceased
- 2015-06-22 PT PT158117143T patent/PT3157531T/pt unknown
- 2015-06-22 PL PL15811714T patent/PL3157531T3/pl unknown
- 2015-06-22 SM SM20210373T patent/SMT202100373T1/it unknown
- 2015-06-22 JP JP2016574402A patent/JP6692300B2/ja active Active
- 2015-06-22 RS RS20210819A patent/RS62064B1/sr unknown
- 2015-06-22 CA CA2951720A patent/CA2951720C/en active Active
- 2015-06-22 SI SI201531637T patent/SI3157531T1/sl unknown
- 2015-06-22 HU HUE15811714A patent/HUE054828T2/hu unknown
- 2015-06-22 ES ES15811714T patent/ES2878077T3/es active Active
- 2015-06-22 CN CN201580033333.7A patent/CN106535902B/zh active Active
-
2016
- 2016-12-20 MX MX2021005489A patent/MX2021005489A/es unknown
-
2017
- 2017-05-24 US US15/604,527 patent/US10208080B2/en active Active
- 2017-05-24 US US15/604,489 patent/US10208079B2/en active Active
- 2017-05-24 US US15/604,452 patent/US10196420B2/en active Active
-
2018
- 2018-07-13 US US16/035,537 patent/US10633413B2/en active Active
- 2018-07-18 US US16/039,294 patent/US11440936B2/en active Active
- 2018-12-13 US US16/219,879 patent/US20190185513A1/en not_active Abandoned
- 2018-12-13 US US16/219,848 patent/US10975116B2/en active Active
- 2018-12-14 US US16/220,860 patent/US20190194244A1/en not_active Abandoned
-
2020
- 2020-01-21 JP JP2020007206A patent/JP7010979B2/ja active Active
-
2021
- 2021-06-28 CY CY20211100573T patent/CY1124554T1/el unknown
-
2022
- 2022-04-01 US US17/711,891 patent/US20220220148A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
| PT3157531T (pt) | Métodos e composições para estimulação do sistema enteroendócrino intestinal para tratamento de doenças ou condições relacionadas com o mesmo | |
| PL3349783T3 (pl) | Kompozycje i sposoby do leczenia chorób | |
| IL253244A0 (en) | Methods for treating retinal diseases | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| IL257561A (en) | Methods for treating inflammatory diseases | |
| IL285003A (en) | Treatment of episode disorders | |
| IL253118A0 (en) | Methods for treating inflammatory diseases | |
| HUE059303T2 (hu) | Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére | |
| GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
| IL253847A0 (en) | Methods of treating diseases | |
| ZA201705877B (en) | Method of treating diseases | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| PT3209295T (pt) | Métodos de tratamento das condições oculares | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| IL251135A0 (en) | A method for the synthesis of hydroxy-triglycerides and their use for the prevention and treatment of diseases | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
| HK1236807A1 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
| GB201516303D0 (en) | Compositions and methods relating to the treatment of diseases | |
| AP2016009662A0 (en) | Combination of taurine and racemethionine for treatment of liver diseases | |
| GB201516437D0 (en) | Compositions and methods relating to the treatment of disease | |
| EP3223828A4 (en) | Methods for the treatment and prevention of asbestos-related diseases |